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ABSTRACT
A human liver cDNA library was used to isolate a clone coding for apolipoprotein A-I (Apo A-I). The clone
carries the sequence for the prepeptide (18 amino acids), the propeptide (6 amino acids), and the mature pro-
tein (243 amino acids). A coding cassette for the proapo A-I molecule was reconstructed by fusing synthetic
sequences, chosen to optimize expression and specifying the amino-terminal methionine and amino acids -6
to +14, to a large fragment of the cDNA coding for amino acids 15-243. The module was expressed in
pOTS-Nco, an Escherichia coli expression vector carrying the regulatable X P^ promoter, leading to the pro-
duction of proapolipoprotein A-I at up to 10% of total soluble proteins. The recombinant polypeptide was
purified and characterized in terms of apparent molecular mass, isoelectric point, and by both chemical and
enzymatic peptide mapping. In addition, it was assayed in vitro for the stimulation of the enzyme lecithin:
cholesterol acyltransferase. The data show for the first time that proapo A-I can be produced efficiently in
E. coli as a stable and undegraded protein having physical and functional properties indistinguishable from
those of the natural product.
INTRODUCTION is responsible for the formation of most of the cholesteryl
esters in plasma (Fielding et al, 1972). Apo A-I and HDL
Human apolipoprotein A-I (apo A-I), the major pro- may participate in "reverse cholesterol transport," from pe-tein constituent of high-density lipoproteins (HDL), ripheral tissues to the liver for excretion from the body
is produced in liver and intestine as a precursor protein (Glomset, 1968).(preproapo A-I) which undergoes intracellular cleavage Since accumulation of cholesterol in the arteries is the
and is released into the plasma and lymph as a proprotein hallmark and presumably an important cause for athero-(Wu and Windmueller, 1979). Proapo A-I carries six addi- sclerosis, stimulation of reverse cholesterol transport by
tional amino acids (Arg-His-Phe-Trp-Gln-Gln) at the supplementing apo A-I might delay the atherosclerotic
amino-terminal of the mature protein. It is cleaved in the process. Techniques to produce this protein in large quan-
vascular space by a specific protease to yield the mature tities have been developed using blood plasma as starting
molecule (Gordon et al, 1983; Zannis et al, 1983). Apo material (Ross and Carson, 1985; Brewer et al, 1986). At-
A-I is a single nonglycosylated polypeptide of known se- tempts to express mature apo A-I in recombinant bacteria
quence, composed of 243 amino acid residues (Brewer et proved difficult due to the instability of the protein
ai, 1978). In the presence of synthetic liposomes, it serves (Lorenzetti et al, 1986; Mallory et al., 1987); moreover,
as cofactor for lecithin ¡cholesterol acyltransferase, which even as a fusion protein, apo A-I was still very sensitive to
•Service de Génétique Appliquée, Université Libre de Bruxelles, 24 rue de l'Industrie, B-1400 Nivelles, Belgium.tu.C.B. and U.C.B. Bioproducts, chemin du Foriest, B-1420 Braine-l'AUeud, Belgium.ÍKing Gustaf V Research Institute, Karolinska Institute, Box 60004, S-10400 Stockholm, Sweden.
429
430 MOGUILEVSKY ET AL.
degradation and could not be cleaved efficiently from the
fusion (Lorenzetti et al., 1986; Monaco et al, 1987). To
circumvent these problems, we expressed apo A-I as the
proprotein. We show here that proapo A-I can be pro-
duced efficiently in Escherichia coli as a stable and unde-
graded molecule, having physical and functional properties
identical to those of the natural product.
MATERIALS AND METHODS
Plasmids, strains, and media
Three plasmids, pBR322 (Bolivar et al., 1977),
pULB1221 (a multi-cloning site derivative of pULB1219,
Cravador et al., 1985), pOTS-Nco (Devare et al, 1984),
and three E. coli strains, MM294 (Lawn et al., 1981),
AR58, and AR120 (Mott et al, 1985), were used. M33
minimal medium is described by Fujimoto et al. (1988).
RNA preparation; synthesis, cloning,
screening, and sequencing of cDNA
Procedures to prepare and screen the human liver cDNA
library were as described before (Jacobs et al, 1985).
Oligonucleotides were synthesized by the phosphoramidite
method on an Applied Biosystem Synthesizer, model 380A
(Matteucci and Caruthers, 1981). DNA sequence analysis
was performed by the methods of Maxam and Gilbert
(1977) and Sanger et al. (1977).
Immunological detection ofproapo A-I in
bacterial extracts
Transformed bacterial strains were grown in 20 ml of
rich (LB) or minimal medium supplemented with ampicil-
lin (50 /ig/ml) to an OD630 of 0.6. Induction of the X PL
promoter was achieved either by shifting the temperature
from 30°C to 42°C, or by adding nalidixic acid (60 fig/ml)
to cells grown at 37°C (Mott et al., 1985). Induction was
performed for various periods of time as indicated in the
figure legends.
One-milliliter aliquots of cultures were collected and
centrifuged at 10,000 x g for 5 min. Pellets were resus-
pended in 50 ¡A of NaDodS04 sample buffer (50 mM Tris
HC1 pH 6.8 containing 2% NaDodS04, 6 M urea, 5% 2-
mercaptoethanol, and 10% glycerol), boiled for 3 min at
100°C, and centrifuged for 10 min at 15,000 x g. Samples
were then fractionated by electrophoresis on 12.5 or 7.5%
NaDodS04-polyacrylamide gels as described by Laemmli(1970).
The proteins were blotted onto nitrocellulose sheets and
tested for the presence of proapo A-I with antibodies
raised against plasma apo A-I. The procedure follows Bol-
len et al. (1984), except that the second antibody, goat
antimouse, was labeled with alkaline phosphatase instead
of peroxidase, and that the chromogenic substrates were
BCIP (5-bromo-4-chloro-3-indolyl-phosphate, Boehringer)
and NBT (4-nitrotetrazolium-chloride blue, Sigma), dis-
solved in 100 mM Tris-HCl pH 9.5, 100 mM NaCl, and 50
mM MgCl2 at 66 and 33 fig/ml, respectively.
Purification of recombinant proapo A-I
Packed bacterial cells (usually 35 grams), derived from
15-liter fermentations in M33 medium, were resuspended
in two volumes of ice-cold extraction buffer (20 mM Tris-
HCl pH 7.5, 100 mM NaCl, 1 mMEDTA, 1 mM PMSF,
and 100 ¡ig/ml merthiolate) and disrupted by a single pas-
sage through a French's pressure cell at 1,000 PSIG. The
extract was centrifuged for 15 min at 4,000 x g to sedi-
ment membranes and aggregates then applied onto a
Phenyl Sepharose column CL-4B (bed volume, 25 ml;
sample, 100 ml). The column was then sequentially eluted
with 250 ml of extraction buffer, 250 ml of the same buffer
supplemented with 60% (vol/vol) propylene glycol, and
250 ml of the same buffer without NaCl and supplemented
with 80% (vol/vol) propylene glycol. Fractions containing
proapo A-I were pooled and then applied onto a PBE 74
chromatofocusing column (0.8 x 60 cm), which was
eluted with two bed volumes of a buffer containing 25 mM
imidazole-HCl pH 6.0 and 6 M urea, followed by 10 bed
volumes of polybuffer 74 (dilution 1/10) pH 4.0, 6 Murea.
The column was regenerated by washing with 50 mM Na-
citrate pH 4.0, 1 M NaCl, and 6 M urea. Fractions were
assayed for total protein content and apo A-I-related im-
munoreactivity, and analyzed by isoelectric focusing.
Chemical peptide mapping with BNPS-Skatol
Chemical cleavage with BNPS-Skatol was performed ac-
cording to the procedure of Fontana (1972). Briefly, 5-10
fig of protein were dissolved in 100 ¡A of a solution of
0.15% (vol/vol) phenol in 50% (vol/vol) acetic acid. Then,
50 fA of a solution of 4.8 mg BNPS-Skatol per milliliter of
glacial acetic acid were added, followed by an incubation
of 72 hr at 25°C. Subsequently, 50 ¡A of 2-mercaptoetha-
nol was added, followed by a second incubation of 5 h at
37°C. The samples were evaporated, redissolved in 100 fA
of water, and extracted three times with 200 ^tl of ethyl ace-
tate. The organic phases were discarded, whereas the aque-
ous phases were lyophilized and analyzed by acrylamide
gel electrophoresis.
Stimulation of lecithin:cholesterol acyltransferase
activity by recombinant proapo A-I
Human plasma apo A-I was purified according to
Holmquist and Carlson (1977) and Holmquist and Bro-
strom (1979). Simple bilayer vesicles containing egg leci-
thin and 7(/i)-3H-labeled cholesterol (molar ratio 4:1) were
prepared according to Batzri and Korn (1973). Highly
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purified human plasma lecithin:cholesterol acyltransferase(35,000 units/mg) was prepared according to Holmquist(1987). Incubations and enzyme activity determinations
were carried out in 50 mM phosphate buffer pH 7.4 as de-
scribed by Piran and Morin (1979). Incubation mixtures
(250 fA) contained per liter: 240 /¿moles lecithin, 60 /¿moles
cholesterol, and 3 or 6 /¿moles apolipoprotein.
Miscellaneous procedures
Protein concentrations were determined according to the
procedure of Bradford (1976), using ovalbumin as a stan-
dard. Partial tryptic hydrolysis was performed according
to the procedure of Amons et al. (1983). Human apo A-I-
related immunoreactivity was quantified by radial immu-
nodiffusion (Cheung and Albers, 1977), using commercial
apo A-I (Sigma) as a standard. The relative immunoreac-
tivity profile were determined by immunoturbidimetry
(Shapiro et al, 1980). Isoelectric focusing was carried out
according to the procedure of Catsimpoolas (1968) in a
Biorad rod electrophoresis apparatus, applying a self-gen-
erating gradient from pH 4 to pH 6. Linear and nonlinear
regression analyses were performed with the StatView pro-
gram (Brain Power Inc., USA).
RESULTS
Molecular cloning of Apo A-I cDNA and screening
of the cDNA library
Total poly(A)*RNA (25 fig) from human liver was tran-
scribed into double-stranded cDNA (ds cDNA). Molecules
resistant to S, nuclease were then fractionated on a 10-
30% sucrose gradient to enrich for molecules larger than
0.8 kb. This ds cDNA fraction was inserted into the Pst I
site of pBR322 by the dC:dG tailing procedure and used to
transform E. coli MM294 cells. The library was screened
by the colony hybridization method using a 22-base syn-
thetic oligonucleotide probe derived from the sequence for
apo A-I (Cheung and Chan, 1983) and coding for amino
acids -22 to -15 of the signal peptide. Of the 30 clones
hybridizing with the labeled probe, one, pNIV1602, was
chosen for further analysis.
Characterization of the clone pNIV1602
Clone pNIV1602 carried an insert of 878 bp which could
be isolated as a single fragment by digesting the plasmid
with Pst I. The insert was mapped with various restriction
enzymes and fully sequenced on each strand. The data (not
shown) showed that pNIV1602 carries (i) a 19-bp 5' non-
coding sequence, (ii) a 75-bp sequence corresponding to
the known signal and propeptide region of apo A-I, in-
cluding the ATG initiation codon, (iii) the complete 729-bp
sequence corresponding to the mature protein, followed by
a TGA stop codon, and (iv) a 55-bp 3' noncoding sequence
that did not contain the poly(A) stretch. The sequence of
the cDNA insert was identical to the sequence published by
Cheung and Chan (1983), but differed from the sequence
of Seilhamer et al. (1984) by a few bases and by the length
of the 5' and 3' noncoding regions. The deduced amino
acid sequence, however, was consistent with the published
data (Cheung and Chan, 1983; Seilhamer et al., 1984).
Construction of the recombinant plasmid pNIVl617
The construction proceeded in two steps. The first used
the multi-cloning site plasmid pULB1221, linearized with
Bal I, as an intermediate vehicle to subclone a blunt-ended
744-bp Bal l-Pst I DNA fragment derived from the clone
pNIV1602 and coding for amino acids 15-243 of the apo
A-I protein. The resulting plasmid was digested with Eco
RI and Bal I and fused to (i) the 1,880-bp Eco Rl-Nco I
DNA fragment containing the regulatory regions derived
from the expression vector pOTS-Nco (Devare et al., 1984)
and (ii) a 65/61-bp Nco l-Bal I synthetic DNA adaptor en-
coding the amino-terminal methionine and amino acids -6
to 14 of proapo A-I (Fig. 1). The resulting recombinant
plasmid, pNIV1617, thus carried the strong regulatable X
Pl promoter upstream from the cassette coding for proapo
A-I.
The synthetic adaptor was assembled from four oligonu-
cleotides (Fig. 2) whose base sequence was designed by
computer to minimize secondary structures at the 5' end of
the coding sequence (S.A.S.I.P. software package; Clav-
erie, 1984). Triplets encoding amino acid residues -6, -1,
1, 3, 4, 5, 6, 7, 10, 11, and 14, therefore differed from the
natural ones (Table 1), although the resulting amino acid
sequence was preserved.
Plasmid pNIV1617 was characterized by restriction anal-
ysis, hybridization with labeled synthetic DNA fragments,
and sequenced throughout the adaptor region. It was then
introduced into E. coli AR58 (for thermal induction) and
AR120 (for chemical induction).
Expression ofproapo A-I
Cells carrying either the control plasmid, pOTS-Nco, or
the pNIV1617 plasmid were grown at 30°C in minimal me-
dium, for thermal induction, or at 37°C in rich medium,
for chemical induction. Derepression of the X PL promoter
was achieved either by shifting the temperature to 42°C or
by adding nalidixic acid. Induction was performed for var-
ious periods of time as indicated in the legend to Fig. 3.
Pelleted bacteria were lysed and the resulting extracts were
analyzed by NaDodS04-polyacrylamide gel electrophore-
sis, Western blotting, and immunodetection using antibod-
ies raised against plasma apo A-I. Figure 3 shows that a
single product, specifically recognized by anti-apo A-I
antibodies, is expressed in the bacterial strains carrying
plasmid pNIV1617, irrespective of the mode of induction.
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(1 BBkb)
proapo A-l
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The protein had a molecular mass of about 28,000 daltons
which, within experimental limits, fitted the calculated mo-
lecular weight of proapo A-I.
Levels of proapo A-I produced in bacteria were esti-
mated by single radial immunodiffusion. Under thermal
induction conditions in M33 minimal medium, proapo A-I
was expressed at about 10% of total soluble proteins
versus 3.5% in LB medium. Chemical induction appeared
to be less efficient, yielding expression levels on the order
of 2% in LB medium and no expression in M33 medium.
Purification of recombinant proapo A-I
We used hydrophobic interaction chromatography to
purify the recombinant proapo A-I. This approach al-
lowed an excellent separation of recombinant molecules
from other bacterial constituents (Fig. 4, peak III). Chro-
matofocusing on a PBE-74 column was used to purify the
product further. As shown in Fig. 5, immunoreactive ma-
FIG. 1. Construction of plasmid pNIV1617. A 744-bp
Bal l-Pst I fragment derived from clone pNIV1602, coding
for amino acids 15-243 of apo A-I, was ligated into the
unique Bal I site of pULB1221. From the resulting plas-
mid, the large Eco Rl-Bal I fragment was fused to the
1,880-bp Eco Rl-Nco I fragment derived from pOTS-Nco
and to the synthetic adaptor Nco l-Bal I to regenerate a se-
quence coding for proapo A-I. Hybrid molecules were
used to transform E. coli cells and transformants were se-
lected for ampicillin resistance. The nucleotide sequence of
the junctions between fragments and of the full synthetic
fragment were determined.
Ncol site
5-- -35 mer
Bal I site
-3'5' -30 mer-
C ATG AGA CAT TTC TGG CAG CAG GAC GAA CCT CCA C AA TCT CCT TGG GATAGA GTT AAG GAC TTG G
TCT GTA AAGACC GTC GTC CTG CTTGGA GGT G TT AGAGGAACC CTATCT CAATTCCTGAAC C
3"-18 met--53-"- 43 mer-»5
Met Arg His Phe Trp Gin Gin
6 -3 1
NH-, terminal propeptide
methionine " 6 aa 1 '
Asp Glu Pro Pro Gin Ser Pro Trp Asp Arg Val Lys Asp Leu A(la)
»1 + 3 +6 +9 +12 +14
mature apo A-l (aa.
-
"14
cleavage site
for apoA I propeptidase
FIG. 2. Synthetic adaptor used to reconstruct the proapo A-I cDNA. Four oligomers were synthesized and assembled
in vitro to generate a 65/61-bp fragment flanked by a Nco I and a Bal I sites on the 5' and 3' ends, respectively. The de-duced amino acid sequence is indicated. The arrow shows the known cleavage site for apo A-I propeptidase (Gordon et
al, 1983; Zannis et al., 1983).
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Table 1. Relevant Changes in Codons Used to Reconstruct
the Proapo A-I cDNA
Position in
the protein Amino acid Natural codon Modified codon
-6
-1
1
2
3 and 4
5
6
7
8
9
10
11
12
13
14
Arg
Gin
Asp
Glu
Pro
Gin
Ser
Pro
Trp
Asp
Arg
Val
Lys
Asp
Leu
CGG
CAÁ
GAT
GAA
CCC
CAG
AGC
CCC
TGG
GAT
CGA
GTG
AAG
GAC
CTG
AGA
CAG
GAC
CCC and CCA
CAA
TCT
CCT
AGA
GTT
TTG
Modifications in the codon usage were done in order to minimize secondary
structures in the 5' end of the proapo A-I cDNA. The software package
S.A.S.I.P. developed by the Institut Pasteur (Paris) was used (Claverie, 1984).
11 10 987 65432 1 kDa
A
.43
13 12 11 10 9 8 7 6 5 4 3 2 1 kDa
B
_29
.18.4
29
.18.4
FIG. 3. Immunodetection of proapo A-I on Western blots. Protein extracts from induced and noninduced bacteria
carrying plasmid pNIV1617 were prepared for electrophoresis on NaDodS04-polyacrylamide gels. Nitrocellulose blots
were incubated with mouse anti apo A-I serum, followed by alkaline phosphatase-labeled goat anti-mouse and the chro-
mogenic substrate. A. Time course of thermal induction of bacteria carrying pNIV1617 and grown in M33 minimal me-
dium. Lane 1, Plasma derived apo A-I, 500 ng; lanes 2-6, samples taken at 1, 20, 40, 60, and 120 min in noninduction
conditions (30°C); lanes 7-11, samples taken at 1, 20, 40, 60, and 120 min after induction (42°C). B. Time course of
chemical induction (nalidixic acid) of bacteria carrying pNIV1617 and grown in rich LB medium. Lane 1, Plasma derived
apo A-I, 500 ng; lanes 2-7, samples taken at 1, 30, 60, 120, 180, and 240 min in noninduction conditions (37°C); lanes
8-13, samples taken at 1, 30, 60, 120, 180, and 240 min after induction (37°C and nalidixic acid, 60 /¿g/ml).
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terial (fractions 37-48) was resolved from contaminants
and was identified by isoelectric focusing mainly as proapo
A-I. Moreover, chromatofocusing resolved most apo A-I
related isoforms.
Characterization ofpurified recombinant
proapo A-I
Pure recombinant proapo A-I was analyzed by
NaDodS04-polyacrylamide gel electrophoresis and isoelec-
tric focusing. Recombinant proapo A-I behaved as a single
Material Eluted.
Arbitrary Units
h. I
Ccccccccctíí? <ccccCrccCco°co_
20 30
Fraction Number
-•rft>-
40
FIG. 4. Hydrophobie interaction chromatography. A
total of 100 ml of cleared extract of bacterial cells derived
from 15-liter fermentation in M33 medium was subjected
to hydrophobic interaction chromatography as described
in Materials and Methods. The eluate was assayed for total
protein (O) and apo A-I-related immunoreactivity (•).
Peak III contains the majority of the recombinant protein.
polypeptide chain with an apparent molecular mass of(27.3 ±1.1) kD. Mature apo A-I was slightly smaller, hav-
ing an apparent molecular weight of (26.8 ± 1.1) kD. In
isoelectric focusing (data not shown), the recombinant
protein showed one major isoform and one minor isoform,
having isoelectric points of 5.20 and 4.95, respectively. The
relative migration distances of these isoforms coincided
exactly with those of plasma proapo A-I and apo A-I, re-
spectively. Partial chemical cleavage at tryptophan resi-
dues, was performed on recombinant proapo A-I (major
isoform) and on plasma-derived apo A-I. Figure 6 shows
the large peptides of expected molecular weight produced
in both cases by cleavage at positions 8, 50, 72, and 108 in
the proteins. In addition, digestions of recombinant
proapo A-I and of plasma-derived apo A-I with trypsin in
very mild conditions yielded similar patterns of fragments
(data not shown). Thus, both types of experiments suggest
that the recombinant molecule is structurally identical to
its natural counterpart.
Functional analysis of recombinant proapo A-I
Recombinant proapo A-I (pi 5.20) and its minor iso-
form (pi 4.95) were both able to transform synthetic leci-
thin-cholsterol liposomes into substrates for the enzyme
lecithin:cholesterol acyltransferase. As seen in Table 2, the
activation capacity of recombinant apoproteins was similar
to the one observed with authentic human plasma apo A-I.
kDa J
Material Eluted,
Arbitrary Units
T-6
+ 5
30 40 50
Fraction Number
FIG. 5. Phenyl-sepharose chromatography. Peak III of
the phenyl sepharose eluate was subjected to chromatofo-
cusing as described in Materials and Methods. The eluate
was assayed for total protein (O), apo A-I-related immu-
noreactivity (•), and pH (A). Fractions 37-48 contain the
purified recombinant product.
43
30
20.1" ****'**
14-4-
FIG. 6. Chemical and enzymatic characterization of pro-
apo A-I. Purified recombinant proapo A-I and human
plasma apo A-I were subjected to partial chemical peptide
mapping as described in Materials and Methods. Lane 1,
Molecular mass standards (Pharmacia, 14,400-94,000 dal-
tons) indicated by arrows; lane 2, human plasma apo A-I,
untreated; lane 3, human plasma apo A-I, cleaved; lane 4,
recombinant proapo A-I, untreated; lane 5, recombinant
proapo A-I, cleaved.
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Table 2. Stimulation of Lecithin ¡Cholesterol Acyltransferase Activity by
Recombinant Proapo A-I
Source
LCAT Apolipoprotein LCAT activity(nmoles/hr x liters)
Plasma apo A-I
Recombinant proapo A-I
Major isoform (pi 5.20)
Minor isoform (pi 4.95)
25
25
100
100
100
100
100
100
0
3
0
3
6
0
3
6
2.5
250
100
850
1,600
100
700
700
Synthetic liposomes (lecithin/cholesterol, 4:1) were incubated at 37°C for 2-4 hr, in a total vol-
ume of 250 (A, with LCAT (25 units/ml) and various amounts of apo A-I. The initial rate of chole-
steryl ester formation (LCAT activity) was measured according to Piran and Morin (1979).
DISCUSSION
We have cloned a cDNA coding for human preproapo
A-I; its deduced amino acid sequence fits the published
data (Cheung and Chan, 1983; Seilhamer et al., 1984) and
is almost identical to that reported by Brewer et al. (1978).
We constructed a module coding for the proapo A-I mole-
cule and expressed it in E. colt under the control of the
regulatable X PL promoter. Proapo A-I, produced at high
level, was stable, largely undegraded, and indistinguishable
from the natural product in terms of apparent molecular
mass, isoelectric point, and partial peptide map. As expected,
most of the material produced in E. coli was in die propro-
tein form, although the presence of an amino-terminal me-
thionine cannot be excluded yet. The purified protein ap
peared to contain a minor isoform which coincided with
mature apo A-I by isoelectric focusing. However, it is un-
certain if this is due to deamidation or to conversion of the
recombinant protein to mature apo A-I. The high level of
expression observed for proapo A-I in bacteria contrasted
with the relative failure (Lorenzetti et al, 1986; our data,
not shown) to achieve significant expression of a stable,
undegraded mature apo A-I species in the same host. The
dramatically increased expression associated with the pres-
ence of the propeptide sequence might be explained in sev-
eral ways. Transcriptional or translational efficiencies
might be increased due to the extra sequence. Alterna-
tively, the proprotein species might fold more stably in
bacteria than the mature protein and hence be more resis-
tant to degradation. This last hypothesis seems more
probable since pulse-chase experiments have shown that
the half-life of mature apo A-I in bacteria is less than 10
min (Mallory et al, 1987). Our data, in addition, offer di-
rect evidence for the first time that recombinant proapo
A-I is able to stimulate in vitro the enzymatic activity of
lecithin:cholesterol acyltransferase, as efficiently as
plasma-derived apo A-I. In this respect, proapo A-I might
constitute an appropriate substitute to mature apo A-I for
replacement therapy, provided that pharmacological stud-
ies in animal models confirm its functional efficiency.
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